JAK1/JAK2 inhibitors, such as fedratinib (TG101348) [60, 317], which strongly reduce the phosphorylation of both STAT1 and STAT3 [60], have been shown to inhibit ABC-DLBCL growth in vitro and in vivo [313, 316]. Here, JAK1 is linked to diffuse large B-cell lymphoma.